#South Korea #Seoul #Global Expansion #Aesthetics #Classys

Classys Inc. Reports Strong Growth in 2026

Classys Inc., a prominent player in the global medical aesthetics industry, recently announced its financial results for the first nine months of 2026, revealing a noteworthy revenue of KRW 275.7 billion, representing a 13% year-on-year increase. The company, listed on the KOSDAQ under the number 214150, has positioned itself strategically to accelerate its growth trajectory in 2027, focusing on expanding into the Chinese market, enhancing its operations in the U.S. and Europe, launching innovative products, and integrating its direct-operation structures.

Key Financial Highlights

Despite challenges faced in the third quarter, where revenue was approximately KRW 83.0 billion with an operating profit of KRW 27.0 billion, Classys remains optimistic. The overall operating profit for the nine months stood at KRW 108.1 billion, although it reflected a slight decline of 9.4% compared to the previous year. Factors influencing this downturn included a transition period for core products in South Korea and initial costs associated with the company's direct operations in Latin America and Japan.

Expansion into the Chinese Market

As Classys gears up for its inaugural product approval in China, it is anticipated that this market will be crucial for future growth. Regulatory challenges are rising, and only companies that secure formal approvals for their devices can succeed. The company aims to introduce its highly-regarded Volnewmer device soon, with expectations for approval in December. Additionally, discussions with significant local partners regarding distribution agreements are underway. The product lineup will also expand to include the Ultraformer and a new offering, Viclara, targeting a range of procedural demands in this vast market.

Growth in the U.S. and Europe

In the U.S. and European markets, Classys recognizes significant opportunities as penetration remains relatively low. Utilizing its existing customer base acquired through the Everesse (Volnewmer in Korea), the company plans to introduce new products like Viclara and Quadessy sequentially, enhancing its portfolio. Following successful business models in Spain and Turkey, Classys aims to broaden its market footprint in Europe with a competitive lineup that includes Ultraformer, Volnewmer, Quadessy, and Viclara.

Innovations and New Products

Back in South Korea, Classys has launched a full marketing campaign for its new four-wavelength laser device, Fortra, featuring a high-profile celebrity. There is also a strategy in motion to introduce a new Volnewmer tip and a novel procedure protocol in early 2027 to align with device sales, aiming for simultaneous revenue growth across devices and consumables. The company is committed to enhancing its market leadership through innovative products such as a new HIFU offering, which promises higher output than the current Shurink Universe.

Direct Operations in LATAM and Japan

Classys's direct operations in Latin America are expected to normalize as the previous inventory turnover is completed, allowing margins to stabilize. Strategic investments in organizational bolstering and brand positioning will facilitate B2C marketing efforts. In Japan, targeted customer base expansion will center around large clinic chains, aiming for greater sales of Volnewmer and Quadessy.

Leadership and Future Endeavors

Classys's CEO, Jun-oh Yoon, addressed the recent financial challenges, expressing confidence in the company's market presence with over 50,000 units sold globally, including substantial HIFU unit sales. He highlighted the recruitment of new top-level executives and the reorganization of company operations to enhance product innovation and global expansion. Looking ahead, Classys is firmly focused on its dual strategy of penetrating the China market, broadening its offerings in the U.S. and Europe, and launching innovative products to bolster revenue growth and profitability.

For more information about Classys and its product offerings, visit their website.